Are Genetic Vaccines the Right Weapon against COVID-19?
作者信息
Conforti Antonella, Marra Emanuele, Roscilli Giuseppe, Palombo Fabio, Ciliberto Gennaro, Aurisicchio Luigi
机构信息
Evvivax, Rome, Italy; Vitares, Rome, Italy.
Takis, Rome, Italy; Vitares, Rome, Italy.
出版信息
Mol Ther. 2020 Jul 8;28(7):1555-1556. doi: 10.1016/j.ymthe.2020.06.007. Epub 2020 Jun 10.
Abstract
摘要
相似文献
1
Are Genetic Vaccines the Right Weapon against COVID-19?基因疫苗是对抗新冠病毒的正确武器吗？
Mol Ther. 2020 Jul 8;28(7):1555-1556. doi: 10.1016/j.ymthe.2020.06.007. Epub 2020 Jun 10.
2
Keeping track of the SARS-CoV-2 vaccine pipeline. 跟踪 SARS-CoV-2 疫苗研发管线。
Nat Rev Immunol. 2020 Nov;20(11):650. doi: 10.1038/s41577-020-00455-1.
3
The Improbability of the Rapid Development of a Vaccine for SARS-CoV-2.开发针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗快速取得进展的不可能性。
Mol Ther. 2020 Jul 8;28(7):1548-1549. doi: 10.1016/j.ymthe.2020.06.005. Epub 2020 Jun 12.
4
Fast-and-fit vaccines.快速适配疫苗
Nat Biomed Eng. 2020 Aug;4(8):757-758. doi: 10.1038/s41551-020-00605-9.
5
Exploit T cell Immunity for Rapid, Safe and Effective COVID-19 Vaccines.利用T细胞免疫开发快速、安全且有效的新冠疫苗。
Expert Rev Vaccines. 2020 Sep;19(9):781-784. doi: 10.1080/14760584.2020.1825946. Epub 2020 Oct 6.
6
The Race to Develop a COVID-19 Vaccine.新冠疫苗研发竞赛。
Am J Nurs. 2020 Oct;120(10):14-15. doi: 10.1097/01.NAJ.0000718556.85319.00.
7
The race for coronavirus vaccines: a graphical guide.新冠疫苗竞赛：图解指南
Nature. 2020 Apr;580(7805):576-577. doi: 10.1038/d41586-020-01221-y.
8
Understanding COVID-19 vaccine efficacy.了解新冠病毒疫苗的效力。
Science. 2020 Nov 13;370(6518):763-765. doi: 10.1126/science.abe5938. Epub 2020 Oct 21.
9
SARS-CoV-2 immunogenicity at the crossroads.十字路口的新型冠状病毒2型免疫原性
Allergy. 2020 Jul;75(7):1822-1824. doi: 10.1111/all.14360. Epub 2020 May 25.
10
Covid-19 and the race for a vaccine.新冠疫情与疫苗竞赛
Hist Cienc Saude Manguinhos. 2020 Jul-Sep;27(3):715-717. doi: 10.1590/S0104-59702020000400001.
引用本文的文献
1
What Lessons can Be Learned From the Management of the COVID-19 Pandemic?从新冠疫情管理中可以吸取哪些教训？
Int J Public Health. 2025 May 30;70:1607727. doi: 10.3389/ijph.2025.1607727. eCollection 2025.
2
Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review.载有大麻二酚的托珠单抗包覆固体脂质纳米粒作为治疗 COVID-19 的新型药物传递策略：综述。
Front Immunol. 2023 Mar 22;14:1147991. doi: 10.3389/fimmu.2023.1147991. eCollection 2023.
3
Immunogenicity of COVID-eVax Delivered by Electroporation Is Moderately Impacted by Temperature and Molecular Isoforms.通过电穿孔递送的COVID-eVax的免疫原性受到温度和分子异构体的中度影响。
Vaccines (Basel). 2023 Mar 16;11(3):678. doi: 10.3390/vaccines11030678.
4
A linear SARS-CoV-2 DNA vaccine candidate reduces virus shedding in ferrets.线性 SARS-CoV-2 DNA 疫苗候选物可减少雪貂的病毒脱落。
Arch Virol. 2023 Mar 29;168(4):124. doi: 10.1007/s00705-023-05746-1.
5
An overview on the treatments and prevention against COVID-19.关于 COVID-19 的治疗和预防概述。
Virol J. 2023 Feb 8;20(1):23. doi: 10.1186/s12985-023-01973-9.
6
A linear DNA encoding the SARS-CoV-2 receptor binding domain elicits potent immune response and neutralizing antibodies in domestic cats.一种编码严重急性呼吸综合征冠状病毒2（SARS-CoV-2）受体结合域的线性DNA在家猫中引发了强烈的免疫反应和中和抗体。
Mol Ther Methods Clin Dev. 2023 Mar 9;28:238-248. doi: 10.1016/j.omtm.2022.12.015. Epub 2023 Jan 2.
7
Towards novel nano-based vaccine platforms for SARS-CoV-2 and its variants of concern: Advances, challenges and limitations.面向新型基于纳米的SARS-CoV-2及其关注变体疫苗平台：进展、挑战与局限
J Drug Deliv Sci Technol. 2022 Oct;76:103762. doi: 10.1016/j.jddst.2022.103762. Epub 2022 Sep 8.
8
Linear DNA amplicons as a novel cancer vaccine strategy.线性 DNA 扩增子作为一种新型癌症疫苗策略。
J Exp Clin Cancer Res. 2022 Jun 6;41(1):195. doi: 10.1186/s13046-022-02402-5.
9
COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review.COVID-19四期候选疫苗、对SARS-CoV-2变体的有效性、中和抗体、罕见副作用、传统和基于纳米的疫苗平台：综述
3 Biotech. 2022 Jan;12(1):15. doi: 10.1007/s13205-021-03076-0. Epub 2021 Dec 12.
10
COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models.COVID-eVax，一种编码 SARS-CoV-2 RBD 的电穿孔 DNA 疫苗候选物，在动物模型中引发了保护性反应。
Mol Ther. 2022 Jan 5;30(1):311-326. doi: 10.1016/j.ymthe.2021.09.011. Epub 2021 Sep 20.
本文引用的文献
1
Developing Covid-19 Vaccines at Pandemic Speed.以大流行速度研发新冠疫苗。
N Engl J Med. 2020 May 21;382(21):1969-1973. doi: 10.1056/NEJMp2005630. Epub 2020 Mar 30.
2
Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.新型冠状病毒感染肺炎在中国武汉的早期传播动力学。
N Engl J Med. 2020 Mar 26;382(13):1199-1207. doi: 10.1056/NEJMoa2001316. Epub 2020 Jan 29.
3
A Comparison of Plasmid DNA and mRNA as Vaccine Technologies.质粒DNA与mRNA作为疫苗技术的比较
Vaccines (Basel). 2019 Apr 24;7(2):37. doi: 10.3390/vaccines7020037.
4
Engineering DNA vaccines against infectious diseases.工程化针对传染病的 DNA 疫苗。
Acta Biomater. 2018 Oct 15;80:31-47. doi: 10.1016/j.actbio.2018.08.033. Epub 2018 Aug 31.
5
Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors.通过调节黑猩猩腺病毒载体中抗原膜锚定来合理设计寨卡疫苗。
Nat Commun. 2018 Jun 22;9(1):2441. doi: 10.1038/s41467-018-04859-5.
6
The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic.首个获批上市的癌症基因治疗药物——重组人 p53 腺病毒注射液（今又生）：12 年临床应用之路
Hum Gene Ther. 2018 Feb;29(2):160-179. doi: 10.1089/hum.2017.218.
7
Linear doggybone DNA vaccine induces similar immunological responses to conventional plasmid DNA independently of immune recognition by TLR9 in a pre-clinical model.线性犬骨 DNA 疫苗在临床前模型中诱导与传统质粒 DNA 相似的免疫反应，而不受 TLR9 的免疫识别影响。
Cancer Immunol Immunother. 2018 Apr;67(4):627-638. doi: 10.1007/s00262-017-2111-y. Epub 2018 Jan 12.
8
Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia.在利比里亚进行的两种预防埃博拉疫苗的2期安慰剂对照试验。
N Engl J Med. 2017 Oct 12;377(15):1438-1447. doi: 10.1056/NEJMoa1614067.
9
Interval Between Infections and Viral Hierarchy Are Determinants of Viral Interference Following Influenza Virus Infection in a Ferret Model.感染间隔和病毒层级是雪貂模型中流感病毒感染后病毒干扰的决定因素。
J Infect Dis. 2015 Dec 1;212(11):1701-10. doi: 10.1093/infdis/jiv260. Epub 2015 May 5.
10
Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome.开发用于严重急性呼吸系统综合征的重组冠状病毒 S 蛋白受体结合域疫苗的路线图。
Expert Rev Vaccines. 2012 Dec;11(12):1405-13. doi: 10.1586/erv.12.126.
Zotero 插件